Aclaris Therapeutics Inc

8AT

Company Profile

  • Business description

    Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

  • Contact

    701 Lee Road
    Suite 103
    WaynePA19087
    USA

    T: +1 484 324-7933

    E: [email protected]

    https://www.aclaristx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2025

    Employees

    64

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,021.9060.200.76%
CAC 407,285.8644.11-0.60%
DAX 4021,205.86105.16-0.49%
Dow JONES (US)37,982.881,159.35-2.96%
FTSE 1008,275.660.060.00%
HKSE21,395.14338.161.61%
NASDAQ15,728.06558.39-3.43%
Nikkei 22534,279.92450.36-1.30%
NZX 50 Index12,118.9951.070.42%
S&P 5005,116.05166.65-3.15%
S&P/ASX 2007,819.1060.200.78%
SSE Composite Index3,280.344.340.13%

Market Movers